The Global Womens Health Therapeutics Market was valued at USD 44.6 billion in 2024 and is estimated to grow at a CAGR of 4.7% to reach USD 69.5 billion by 2034.
Conditions like endometriosis, menopause-related issues, polycystic ovary syndrome (PCOS), and osteoporosis is increasingly common. This growing disease burden is pushing demand for more effective and targeted therapeutics.
Major players in the women’s health therapeutics market are Theramex, Cipla, Kissei Pharmaceutical, Evofem, Pfizer, Shionogi, Ferring, Organon, Amgen, Besins, Allergan (AbbVie), Sanofi, Gedeon Richter, Lupin, Atossa Therapeutics, Novartis, Johnson & Johnson, and Bayer.
To strengthen their market foothold in the women’s health therapeutics space, companies are focusing on a multi-pronged approach. Key strategies include expanding product pipelines through in-house R&D and licensing deals, particularly for underserved conditions such as uterine fibroids and female sexual dysfunction. Mergers and acquisitions are also being used to consolidate market presence and gain access to innovative technologies.
This product will be delivered within 2-4 business days.
Conditions like endometriosis, menopause-related issues, polycystic ovary syndrome (PCOS), and osteoporosis is increasingly common. This growing disease burden is pushing demand for more effective and targeted therapeutics.
Increasing Adoption of Hormonal Therapies
The hormonal therapies segment held a significant share in 2024, driven by the rising demand for treatments that address conditions such as menopause symptoms, endometriosis, and hormonal imbalances. As awareness grows around hormone replacement therapy (HRT) and the long-term health impacts of untreated hormonal issues, more women are seeking medical intervention. The market has seen continuous innovation in delivery mechanisms, including patches, gels, and sustained-release implants, which enhance patient compliance.Rising Prevalence of Contraception
The contraception segment generated a sizeable share in 2024, driven by rising demand for both long-acting reversible contraceptives (LARCs) and non-hormonal options. Modern lifestyles, delayed family planning, and growing public health support for reproductive autonomy have fueled adoption across a broad demographic. The market is evolving beyond traditional oral contraceptives, with innovations in vaginal rings, intrauterine devices (IUDs), and injectable formats.Prescription to Gain Traction
The prescription segment held a substantial share in 2024, owing to the clinical nature of most treatments for conditions like osteoporosis, fertility issues, and gynecological cancers. Physicians remain key decision-makers, and patient trust in prescribed medications continues to drive brand loyalty. Regulatory approval pathways, formulary positioning, and insurance coverage significantly impact sales performance in this segment.North America to Emerge as a Propelling Region
North America womens health therapeutics market is poised to grow at a decent CAGR during 2025-2034. The region benefits from advanced healthcare infrastructure, strong regulatory oversight, and high awareness levels among both patients and providers. Market players are capitalizing on favorable reimbursement policies and rising demand for targeted treatments across various stages of a woman's life cycle, from adolescence to post-menopause.Major players in the women’s health therapeutics market are Theramex, Cipla, Kissei Pharmaceutical, Evofem, Pfizer, Shionogi, Ferring, Organon, Amgen, Besins, Allergan (AbbVie), Sanofi, Gedeon Richter, Lupin, Atossa Therapeutics, Novartis, Johnson & Johnson, and Bayer.
To strengthen their market foothold in the women’s health therapeutics space, companies are focusing on a multi-pronged approach. Key strategies include expanding product pipelines through in-house R&D and licensing deals, particularly for underserved conditions such as uterine fibroids and female sexual dysfunction. Mergers and acquisitions are also being used to consolidate market presence and gain access to innovative technologies.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Drug Type, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Medication Type, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Age Group, 2021-2034 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Distribution Channel, 2021-2034 ($ Mn)
Chapter 10 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 11 Company Profiles
Companies Mentioned
The key companies profiled in this Womens Health Therapeutics market report include:- Allergan (AbbVie)
- Amgen
- Atossa Therapeutics
- Bayer
- Besins
- Cipla
- Evofem
- Ferring
- Gedeon Richter
- Johnson & Johnson
- Kissei Pharmaceutical
- Lupin
- Novartis
- Organon
- Pfizer
- Sanofi
- Shionogi
- Theramex
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | September 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 44.6 Billion |
| Forecasted Market Value ( USD | $ 69.5 Billion |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 19 |
